In a filing, Sarepta Therapeutics Inc revealed its Director Nicaise Claude unloaded Company’s shares for reported $0.25 million on Mar 12 ’25. In the deal valued at $99.64 per share,2,491 shares were sold. As a result of this transaction, Nicaise Claude now holds 27,812 shares worth roughly $1.54 million.
Then, Nicaise Claude bought 2,491 shares, generating $248,226 in total proceeds.
Before that, Wigzell Hans Lennart Rudolf sold 10,500 shares. Sarepta Therapeutics Inc shares valued at $1,310,820 were divested by the Director at a price of $124.84 per share. As a result of the transaction, Wigzell Hans Lennart Rudolf now holds 22,840 shares, worth roughly $1.26 million.
Wells Fargo initiated its Sarepta Therapeutics Inc [SRPT] rating to an Overweight in a research note published on April 11, 2025; the price target was $115. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who increased its forecast for the stock in early April from “a Sell” to “a Neutral”. RBC Capital Mkts also remained covering SRPT and has decreased its forecast on March 31, 2025 with a “Sector perform” recommendation from previously “an Outperform” rating. Deutsche Bank started covering the stock on February 11, 2025. It rated SRPT as “a Hold”.
Price Performance Review of SRPT
On Monday, Sarepta Therapeutics Inc [NASDAQ:SRPT] saw its stock jump 2.68% to $55.23. Over the last five days, the stock has gained 8.23%. Sarepta Therapeutics Inc shares have fallen nearly -54.58% since the year began. Nevertheless, the stocks have fallen -53.15% over the past one year. While a 52-week high of $173.25 was reached on 01/07/25, a 52-week low of $48.01 was recorded on 04/09/25. SMA at 50 days reached $84.67, while 200 days put it at $117.32.
Levels Of Support And Resistance For SRPT Stock
The 24-hour chart illustrates a support level at 53.32, which if violated will result in even more drops to 51.40. On the upside, there is a resistance level at 56.63. A further resistance level may holdings at 58.02. The Relative Strength Index (RSI) on the 14-day chart is 34.08, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.55, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 59.16%. Stochastics %K at 33.41% indicates the stock is a holding.
How much short interest is there in Sarepta Therapeutics Inc?
A steep rise in short interest was recorded in Sarepta Therapeutics Inc stocks on 2025-03-31, growing by 1.03 million shares to a total of 6.1 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 5.06 million shares. There was a rise of 16.96%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 27, 2024 when Needham resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $202.
